- Type 2 diabetes is the
most common form of diabetes in the world.
- The efficacy and
safety of omarigliptin, once a week drug in type 2 diabetes treatment was
compared with a daily dose of sitagliptin drug.
- The study
results found 25mg of omarigliptin drug once a week to be an appropriate dose
The efficacy and safety
of a once-week diabetes drug omarigliptin in patients with type 2 diabetes
were compared with the daily drug sitagliptin by a research team from the LMC
Diabetes & Endocrinology, Toronto, Ontario, Canada.
The research findings
were published in the journal Diabetes, Obesity and Metabolism.
‘Weekly diabetes drug omarigliptin found to produce similar benefits as that of sitagliptin drug.’
(DPP-4) inhibitors or gliptins is a class of drugs, which
can be prescribed for the treatment of type 2 diabetes.
Type 2 diabetes
is the most
common form of diabetes that causes elevated blood sugar levels. According to
the World Health Organization statistics, the number of people with diabetes
increased to 422 million in 2014.
The research study was
conducted on type 2 diabetes mellitus patients who took metformin
for treatment. These patients had the HbA1c level between 6.5-9.0% while
screening and had a fasting blood glucose level greater than 7.2 and less than
14.4mmol/liter at randomization.
The research study was
conducted at 97 sites in 13 countries that include 6 in Argentina, 6 in Canada,
1 in Croatia, 5 in Estonia, 5 in Georgia, 10 in Hungary, 4 in Israel, 5 in
Malaysia, 4 in the Philippines, 9 in Poland, 8 in Romania, 8 in South Africa
and 26 in the USA.
A 1- week screening
period, followed by a 2- week single placebo run-in period and 24-week
treatment period was carried out.
After the placebo (dummy
pill which has no active ingredient) period, a 1:1 ratio of either a 25mg of
omarigliptin drug was given once weekly with a placebo matching sitagliptin for
once daily or 100mg of sitagliptin every day with a placebo weekly dose of
Findings of the Study
The study evaluated the
efficacy, safety, tolerability of omarigliptin drug for 24 weeks.The percentage
of patients who received HbA1c levels of less than 7.0% and less than 6.5% were
The study results found
- Patients who took an additional
once weekly omarigliptin drug 25mg had similar reductions in HbA1c level and
fasting blood glucose levels when compared to a daily dose of 100mg sitagliptin.
The efficacy of controlling the blood glucose
levels with DPP-4 drug inhibitors over a period of one week is found to be
similar to that of daily administration. The results also
confirm that 25mg of omarigliptin drug is an appropriate dose to achieve
effective treatment for type2 diabetes .
It is a dipeptidyl
peptidase-4 enzyme inhibitor drug which acts by regulating the incretin
hormones including glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP). These hormones are involved in the
physiological regulation of glucose levels.
The adverse effects of
Omarigliptin drug were well tolerated and the incidence of patients reporting
low blood sugar levels (hypoglycemia) was also similar with the sitagliptin
The drug was
recently approved in Japan as a single weekly dose for diabetes treatment.
Interesting Facts on
- Diabetes is the
leading cause of blindness among working adults.
- Type 2
diabetes account for 85-90% of diabetes among
- Diabetes is one of the common reasons for
amputation and kidney failure.
- Genetic factors, sedentary lifestyle
and obesity are some of the causes for diabetes.
- Diabetic patients are at an increased risk for heart diseases.
Goldenberg et al. 'Randomized clinical trial comparing the efficacy and safety of
treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor
omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with
type 2 diabetes inadequately controlled on metformin monotherapy', Diabetes,
Obesity and Metabolism (2017). DOI:
- What is type2 diabetes? - (http://www.hormone.org/questions-and-answers/2012/dpp-4-inhibitors)
- Facts About
Diabetes - (https://www.iddt.org/about/facts)
- Ten Things You Might Not Know About
Diabetes - (http://www.joslin.org/info/10_Things_You_Might_Not_Know_About_Diabetes.html)